Keywords: belinostat, enters, ph, i/ii, trial, copenhagen, denmark-based
Belinostat enters Ph I/II trial
Article | 03 September 2007
Copenhagen, Denmark-based TopoTarget AS and US firm CuraGen have initiated patient dosing in a Phase I/II trial evaluating belinostat ( ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
